These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1574541)

  • 1. Drug-responsive symptoms during early neuroleptic treatment.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Psychiatry Res; 1992 Feb; 41(2):147-54. PubMed ID: 1574541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Biol Psychiatry; 1991 Sep; 30(5):475-82. PubMed ID: 1932395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
    Bowers MB; Mazure CM; Nelson JC; Jatlow PI
    Biol Psychiatry; 1992 Dec; 32(12):1102-7. PubMed ID: 1477190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
    Mazure CM; Nelson JC; Jatlow PI; Kincare P; Bowers MB
    J Clin Psychiatry; 1990 Aug; 51(8):330-4. PubMed ID: 2199431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychotogenic drug use and neuroleptic response.
    Bowers MB; Mazure CM; Nelson JC; Jatlow PI
    Schizophr Bull; 1990; 16(1):81-5. PubMed ID: 1970670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acutely psychotic patients receiving high-dose haloperidol therapy.
    Remington G; Pollock B; Voineskos G; Reed K; Coulter K
    J Clin Psychopharmacol; 1993 Feb; 13(1):41-5. PubMed ID: 8486816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of haloperidol on human plasma magnesium.
    Jabotinsky-Rubin K; Durst R; Levitin LA; Moscovich DG; Silver H; Lerner J; Van Praag H; Gardner EL
    J Psychiatr Res; 1993; 27(2):155-9. PubMed ID: 8366466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs.
    Maes M; De Meester I; Scharpe S; Desnyder R; Ranjan R; Meltzer HY
    Acta Psychiatr Scand; 1996 Jan; 93(1):1-8. PubMed ID: 8919323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of psychotic symptoms to haloperidol-stimulated prolactin release.
    Kulkarni J; Keks NA; Stuart G; Mackie B; Minas IH; Singh BS; Copolov DL
    Acta Psychiatr Scand; 1990 Oct; 82(4):271-4. PubMed ID: 2260479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological treatment of delusional depression].
    Amore M; Giordani L; Giorgetti G; Zazzeri N
    Minerva Psichiatr; 1996 Mar; 37(1):29-33. PubMed ID: 8804200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial.
    Kramer MS; Vogel WH; DiJohnson C; Dewey DA; Sheves P; Cavicchia S; Little P; Schmidt R; Kimes I
    Arch Gen Psychiatry; 1989 Oct; 46(10):922-8. PubMed ID: 2679483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluvoxamine and perphenazine for psychosis in Alzheimer's disease: pharmacokinetic considerations.
    Baumann P; Eap CB; Zullino DF
    J Nerv Ment Dis; 2001 Nov; 189(11):798-9. PubMed ID: 11758666
    [No Abstract]   [Full Text] [Related]  

  • 13. TSH-response patterns to TRH stimulation may indicate therapeutic mechanisms of antidepressant and neuroleptic drugs.
    Langer G; Resch F; Aschauer H; Keshavan MS; Koinig G; Schönbeck G; Dittrich R
    Neuropsychobiology; 1984; 11(4):213-8. PubMed ID: 6436728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postpsychotic depression and negative symptoms: an investigation of syndromal overlap.
    Siris SG; Adan F; Cohen M; Mandeli J; Aronson A; Casey E
    Am J Psychiatry; 1988 Dec; 145(12):1532-7. PubMed ID: 3057924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria.
    Newcomer JW; Miller LS; Faustman WO; Wetzel MW; Vogler GP; Csernansky JG
    Br J Psychiatry; 1994 Jun; 164(6):834-8. PubMed ID: 7952993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between medication treatments and neuropsychological test performance in schizophrenia.
    Sweeney JA; Keilp JG; Haas GL; Hill J; Weiden PJ
    Psychiatry Res; 1991 Jun; 37(3):297-308. PubMed ID: 1679950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.
    Rothschild AJ; Samson JA; Bessette MP; Carter-Campbell JT
    J Clin Psychiatry; 1993 Sep; 54(9):338-42. PubMed ID: 8104930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of schizoaffective disorders.
    Goodnick PJ; Meltzer HY
    Schizophr Bull; 1984; 10(1):30-48. PubMed ID: 6142525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
    Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
    J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia.
    Balant-Gorgia AE; Eisele R; Balant L; Garrone G
    Eur Arch Psychiatry Neurol Sci; 1984; 234(1):1-4. PubMed ID: 6489392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.